<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="overview is given on the current knowledge of the spread," exact="disease" post="course, and molecular biology of SARS-CoV-2. We discuss potential"/>
 <result pre="a large number of people have died from the virus-induced" exact="pneumonia" post="COVID-19, and the global economy is at an unprecedented"/>
 <result pre="SARS-CoV-2 Outbreak in Wuhan In December 2019, an outbreak of" exact="pneumonia" post="of an unknown cause was reported in Wuhan, in"/>
 <result pre="China. It was speculated that the first patient caught the" exact="infection" post="from a seafood market that also traded wild animals."/>
 <result pre="CoV responsible for the outbreak is now called SARS-CoV-2. The" exact="respiratory" post="illness caused by SARS-CoV-2 is called COVID-19. The symptoms"/>
 <result pre="by SARS-CoV-2 is called COVID-19. The symptoms of the SARS-CoV-2" exact="infection" post="range from asymptomatic to mild to severe to death.1"/>
 <result pre="globe, and as of May 15th led to &amp;gt;4.5 million" exact="infections" post="and 300,000 fatalities. Based on the previous experience with"/>
 <result pre="pathogenic than SARS-CoV, much less pathogenic than the Middle East" exact="respiratory" post="syndrome MERS-CoV, but more pathogenic than practically harmless HCoV-OC43,"/>
 <result pre="than SARS-CoV, much less pathogenic than the Middle East respiratory" exact="syndrome" post="MERS-CoV, but more pathogenic than practically harmless HCoV-OC43, HCoV-HKU1,"/>
 <result pre="and Pandemics Pandemic (Causing Agent) Time Transmission Mortality No. of" exact="Infection" post="Cases No. of Death Cases Black death (Yersinia pestis)14th"/>
 <result pre="50,000â€&quot;575,000 Advice guidelines for diagnosis and treatment of SARS-CoV-2 infected" exact="pneumonia" post="have been shared rapidly.3 What are the issues and"/>
 <result pre="the bodyâ€™s immune system are also a strategy to combat" exact="viral" post="diseases. Again, the typical development timelines are several years."/>
 <result pre="envelope (E) protein, which are needed to produce a structurally" exact="complete" post="viral particle. Additionally, the SARS-CoV-2 genome encodes 16â€&quot;17 non-structural"/>
 <result pre="(E) protein, which are needed to produce a structurally complete" exact="viral" post="particle. Additionally, the SARS-CoV-2 genome encodes 16â€&quot;17 non-structural proteins"/>
 <result pre="FigureÂ 1 Scheme of SARS-CoV-2 and Some of Its Molecular" exact="Protein" post="Targets 3CLpro Both the virus-encoded proteases 3CLpro and PLproÂ"/>
 <result pre="and PLproÂ are involved in the processing of the two" exact="viral" post="polyproteins in a coordinated manner, and thus comprise important"/>
 <result pre="3CLpro is a cysteine protease that cleaves and processes the" exact="viral" post="polyproteins. SARS-CoV-2 and SARS-CoV share 96% sequence identity in"/>
 <result pre="The broad-spectrum and established use of plant-based medicines to combat" exact="infectious diseases" post="in TCM is the basis of several currently ongoing"/>
 <result pre="fructus), which is purported to have been used for treating" exact="infections" post="for more than 2,000 years. FigureÂ 4 Flavonoids Inhibiting"/>
 <result pre="of the SARS-CoV PLpro has been extensively reviewed.25 Although the" exact="primary" post="function of PLpro and 3CLpro is to process the"/>
 <result pre="primary function of PLpro and 3CLpro is to process the" exact="viral" post="polyprotein in a coordinated manner, PLpro has the additional"/>
 <result pre="antiviral drugs might have an advantage in not only inhibiting" exact="viral" post="replication but also inhibiting the dysregulation of signaling cascades"/>
 <result pre="sulfones. Disulfiram (19), an approved drug for the treatment of" exact="chronic" post="alcohol dependence, has a great potential for drug repurposing"/>
 <result pre="Disulfiram (19), an approved drug for the treatment of chronic" exact="alcohol dependence," post="has a great potential for drug repurposing because it"/>
 <result pre="show a rather drug-like appearance (FigureÂ 5 ). FigureÂ 5" exact="Structural" post="Interaction of a Non-covalent Napthylamine Inhibitor with PLpro Co-crystal"/>
 <result pre="by first binding to a host receptor and then fusing" exact="viral" post="and host membranes. The SARS-CoV-2Â S protein was solved"/>
 <result pre="molecules with fusion-inhibiting potential. It is the affinity between the" exact="viral" post="receptor-binding domain (RBD) and the host receptor in the"/>
 <result pre="receptor-binding domain (RBD) and the host receptor in the initial" exact="viral" post="attachment step that primarily determines which host is susceptible"/>
 <result pre="into target cells.31,32 The interplay of the ACE receptor in" exact="cardiovascular" post="diseases (with the well-known drug class of ACE inhibitors)"/>
 <result pre="ACE inhibitors) and as the docking pointÂ for SARS-CoV-2 cellular" exact="infection" post="is a current point of intense debate and research.33"/>
 <result pre="the consensus target antigen. RdRp The RdRp enzyme allows the" exact="viral" post="genome to be transcribed into new RNA copies by"/>
 <result pre="RdRp inhibitors are emerging as a new strategy to fight" exact="viral" post="infections.35 The chemistry and biology of RdRp have been"/>
 <result pre="nucleotide favipiravir-ribofuranosyl-5-triphosphate that inhibits the RNA replication and thus the" exact="viral" post="progression.38 Interestingly, it does not inhibit host DNA and"/>
 <result pre="emerged novel CoV (SARS-CoV-2) inÂ vitro.40,41 Remdesivir (25) reduced SARS-CoV-2" exact="infection" post="of monkey kidney cells with an EC50 of 0.77Â"/>
 <result pre="remdesivir is pre-mature RNA synthesis termination by incorporation into nascent" exact="viral" post="RNA chains.42 Galidesivir (26) is another antiviral drug under"/>
 <result pre="an adenosine analog and is currently developed for Ebola virus" exact="disease" post="and Marburg virus disease. It also shows broad-spectrum antiviral"/>
 <result pre="analog and is currently developed for Ebola virus disease and" exact="Marburg virus disease." post="It also shows broad-spectrum antiviral activity against RNA virus"/>
 <result pre="shows broad-spectrum antiviral activity against RNA virus families including CoVs.43" exact="Multiple" post="other RdRp inhibitors are described in the literature, for"/>
 <result pre="medicine also used to treat several other diseases. It blocked" exact="virus infection" post="with an EC50 of 1.13Â Î¼M.40,41 Its mode of"/>
 <result pre="also used to treat several other diseases. It blocked virus" exact="infection" post="with an EC50 of 1.13Â Î¼M.40,41 Its mode of"/>
 <result pre="inhibits endosomal acidification and thus could stop the release of" exact="viral" post="DNA into the cytoplasm. It is under assessment in"/>
 <result pre="for an additional study in Hunan province are underway. Other" exact="Viral" post="Proteins The role of the other SARS-CoV-2Â N proteins"/>
 <result pre="a vast interaction network described between the non-structural proteins. Similarly," exact="viral" post="particle assembly requires orchestrated interaction between N, S, M,"/>
 <result pre="It is rapidly detected by antibodies in serum, plasma, and" exact="peripheral" post="blood, and might therefore serve to develop specific diagnostics."/>
 <result pre="be able to treat severely sick people. References References 1LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
 <result pre="able to treat severely sick people. References References 1LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
 <result pre="to treat severely sick people. References References 1LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
 <result pre="J. Antimicrob. Agents55202010592432081636 2LiuP.ChenW.ChenJ.P.Viral metagenomics revealed Sendai virus and coronavirus" exact="infection" post="of Malayan pangolins (Manis javanica)Viruses112019979 3JinY.H.CaiL.ChengZ.S.ChengH.DengT.FanY.P.FangC.HuangD.HuangL.Q.HuangQ.A rapid advice guideline"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Mil. Med. Res.72020432029004 4PushpakomS.IorioF.EyersP.A.EscottK.J.HopperS.WellsA.DoigA.GuilliamsT.LatimerJ.McNameeC.Drug repurposing: progress, challenges and"/>
 <result pre="novel coronavirus (2019-nCoV)Nat. Rev. Drug Discov.19202014915032127666 6PillaiyarT.ManickamM.NamasivayamV.HayashiY.JungS.H.An overview of severe" exact="acute" post="respiratory syndromeâ€&quot;coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small"/>
 <result pre="coronavirus (2019-nCoV)Nat. Rev. Drug Discov.19202014915032127666 6PillaiyarT.ManickamM.NamasivayamV.HayashiY.JungS.H.An overview of severe acute" exact="respiratory" post="syndromeâ€&quot;coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule"/>
 <result pre="Med. Chem.1820107849785420947359 12ShieJ.J.FangJ.M.KuoC.J.KuoT.H.LiangP.H.HuangH.J.YangW.B.LinC.H.ChenJ.L.WuY.T.WongC.H.Discovery of potent anilide inhibitors against the severe" exact="acute" post="respiratory syndrome 3CL proteaseJ.Â Med. Chem.4820054469447315974598 13JacobsJ.Grum-TokarsV.ZhouY.TurlingtonM.SaldanhaS.A.ChaseP.Discovery, synthesis, and"/>
 <result pre="Chem.1820107849785420947359 12ShieJ.J.FangJ.M.KuoC.J.KuoT.H.LiangP.H.HuangH.J.YangW.B.LinC.H.ChenJ.L.WuY.T.WongC.H.Discovery of potent anilide inhibitors against the severe acute" exact="respiratory" post="syndrome 3CL proteaseJ.Â Med. Chem.4820054469447315974598 13JacobsJ.Grum-TokarsV.ZhouY.TurlingtonM.SaldanhaS.A.ChaseP.Discovery, synthesis, and structure-based"/>
 <result pre="12ShieJ.J.FangJ.M.KuoC.J.KuoT.H.LiangP.H.HuangH.J.YangW.B.LinC.H.ChenJ.L.WuY.T.WongC.H.Discovery of potent anilide inhibitors against the severe acute respiratory" exact="syndrome" post="3CL proteaseJ.Â Med. Chem.4820054469447315974598 13JacobsJ.Grum-TokarsV.ZhouY.TurlingtonM.SaldanhaS.A.ChaseP.Discovery, synthesis, and structure-based optimization"/>
 <result pre="(ML188) as potent noncovalent small molecule inhibitors of the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) 3CL protease.J. Med. Chem.56201353454623231439 14BerryM.FieldingB.C.GamieldienJ.Potential"/>
 <result pre="as potent noncovalent small molecule inhibitors of the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) 3CL protease.J. Med. Chem.56201353454623231439 14BerryM.FieldingB.C.GamieldienJ.Potential broad"/>
 <result pre="potent noncovalent small molecule inhibitors of the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) 3CL protease.J. Med. Chem.56201353454623231439 14BerryM.FieldingB.C.GamieldienJ.Potential broad spectrum"/>
 <result pre="of SARS: initial virological and clinical findingsThorax59200425225614985565 20ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.TseM.W.QueT.L.PeirisJ.S.SungJ.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
 <result pre="SARS: initial virological and clinical findingsThorax59200425225614985565 20ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.TseM.W.QueT.L.PeirisJ.S.SungJ.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
 <result pre="initial virological and clinical findingsThorax59200425225614985565 20ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.TseM.W.QueT.L.PeirisJ.S.SungJ.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
 <result pre="the binding effect of ritonavir, lopinavir and Darunavir to severe" exact="acute" post="respiratory syndrome coronavirus 2 proteasesbioRxiv202010.1101/2020.01.31.929695 23CaoB.WangY.WenD.LiuW.WangJ.FanG.A trial of lopinavirâ€&quot;ritonavir"/>
 <result pre="binding effect of ritonavir, lopinavir and Darunavir to severe acute" exact="respiratory" post="syndrome coronavirus 2 proteasesbioRxiv202010.1101/2020.01.31.929695 23CaoB.WangY.WenD.LiuW.WangJ.FanG.A trial of lopinavirâ€&quot;ritonavir in"/>
 <result pre="effect of ritonavir, lopinavir and Darunavir to severe acute respiratory" exact="syndrome" post="coronavirus 2 proteasesbioRxiv202010.1101/2020.01.31.929695 23CaoB.WangY.WenD.LiuW.WangJ.FanG.A trial of lopinavirâ€&quot;ritonavir in adults"/>
 <result pre="with severe Covid-19N.Â Engl. J. Med.38220201787179932187464 24RabiF.A.Al ZoubiM.S.KasasbehG.A.SalamehD.M.Al-NasserA.D.SARS-CoV-2 and coronavirus" exact="disease" post="2019: what we know so farPathogens92020231 25BÃ¡ez-SantosY.M.St JohnS.E.MesecarA.D.The SARS-coronavirus"/>
 <result pre="selective inhibitors of human coronavirus papain-like proteasesJ.Â Med. Chem.5720142393241224568342 29GhoshA.K.TakayamaJ.RaoK.V.RatiaK.ChaudhuriR.MulhearnD.C.LeeH.NicholsD.B.BalijiS.BakerS.C.Severe" exact="acute" post="respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis,"/>
 <result pre="inhibitors of human coronavirus papain-like proteasesJ.Â Med. Chem.5720142393241224568342 29GhoshA.K.TakayamaJ.RaoK.V.RatiaK.ChaudhuriR.MulhearnD.C.LeeH.NicholsD.B.BalijiS.BakerS.C.Severe acute" exact="respiratory" post="syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand"/>
 <result pre="of human coronavirus papain-like proteasesJ.Â Med. Chem.5720142393241224568342 29GhoshA.K.TakayamaJ.RaoK.V.RatiaK.ChaudhuriR.MulhearnD.C.LeeH.NicholsD.B.BalijiS.BakerS.C.Severe acute respiratory" exact="syndrome" post="coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray"/>
 <result pre="decade-long structural studies of SARS CoronavirusJ.Â Virol.942020e00127â€&quot;20 33ZhengY.Y.MaY.T.ZhangJ.Y.XieX.COVID-19 and the" exact="cardiovascular" post="systemNat. Rev. Cardiol.17202025926032139904 34GrubaughN.D.PetroneM.E.HolmesE.C.We shouldnâ€™t worry when a virus"/>
 <result pre="Rev. Cardiol.17202025926032139904 34GrubaughN.D.PetroneM.E.HolmesE.C.We shouldnâ€™t worry when a virus mutates during" exact="disease" post="outbreaksNat. Microbiol.5202052953032071422 35JordanP.C.StevensS.K.DevalJ.Nucleosides for the treatment of respiratory RNA"/>
 <result pre="mutates during disease outbreaksNat. Microbiol.5202052953032071422 35JordanP.C.StevensS.K.DevalJ.Nucleosides for the treatment of" exact="respiratory" post="RNA virus infectionsAntivir. Chem. Chemother.2620182040206618764483 36GiacchelloI.MusumeciF.D'AgostinoI.GrecoC.GrossiG.SchenoneS.Insights into RNA-dependent RNA"/>
 <result pre="38FurutaY.TakahashiK.ShirakiK.SakamotoK.SmeeD.F.BarnardD.L.GowenB.B.JulanderJ.G.MorreyJ.D.T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA" exact="viral" post="infectionsAntiviral Res.8220099510219428599 39ZhangY.F.Potential coronavirus drug approved for marketing. China"/>
 <result pre="molecule GS-5734 against Ebola virus in rhesus monkeysNature531201638138526934220 43WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits" exact="Rift Valley fever" post="virus infection and disease in Syrian golden hamstersAntiviral Res.1562018384529864447"/>
 <result pre="Ebola virus in rhesus monkeysNature531201638138526934220 43WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits Rift Valley fever" exact="virus infection" post="and disease in Syrian golden hamstersAntiviral Res.1562018384529864447 44YoonJ.S.KimG.JarhadD.B.KimH.R.ShinY.S.QuS.SahuP.K.KimH.O.LeeH.W.WangS.B.Design, synthesis,"/>
 <result pre="virus in rhesus monkeysNature531201638138526934220 43WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits Rift Valley fever virus" exact="infection" post="and disease in Syrian golden hamstersAntiviral Res.1562018384529864447 44YoonJ.S.KimG.JarhadD.B.KimH.R.ShinY.S.QuS.SahuP.K.KimH.O.LeeH.W.WangS.B.Design, synthesis,"/>
 <result pre="rhesus monkeysNature531201638138526934220 43WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits Rift Valley fever virus infection and" exact="disease" post="in Syrian golden hamstersAntiviral Res.1562018384529864447 44YoonJ.S.KimG.JarhadD.B.KimH.R.ShinY.S.QuS.SahuP.K.KimH.O.LeeH.W.WangS.B.Design, synthesis, and anti-RNA"/>
 <result pre="unique drug targeting sitesbioRxiv202010.1101/2020.03.06.977876v2 46RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet3952020e30e3132032529 47ZumlaA.ChanJ.F.AzharE.I.HuiD.S.YuenK.Y.Coronaviruses â€&quot; drug discovery and therapeutic optionsNat."/>
 <result pre="drug targeting sitesbioRxiv202010.1101/2020.03.06.977876v2 46RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet3952020e30e3132032529 47ZumlaA.ChanJ.F.AzharE.I.HuiD.S.YuenK.Y.Coronaviruses â€&quot; drug discovery and therapeutic optionsNat. Rev."/>
</results>
